EMPE Diagnostics

Solna, Sweden Founded: 2015 • Age: 11 yrs
Point-of-care tests for TB mutation detection are developed.
Annual revenue $693,331 Latest available
Total funding $1.2M 5 rounds
Employees 27 Tracked headcount
Investors 3 Known backers
Products - Services tracked
Competitors 11 Brand Intelligence

About EMPE Diagnostics

EMPE Diagnostics is a company based in Solna (Sweden) founded in 2015 by Pavan Asalapuram. EMPE Diagnostics has raised $1.15 million across 5 funding rounds from investors including European Union, EIC Fund and Almi Invest. The company has 27 employees as of April 05, 2024. EMPE Diagnostics operates in a competitive market with competitors including OpGen, QuantuMDx, Oxford Immunotec, Avails Medical and Resistell, among others.

  • Headquarter Solna, Sweden
  • Employees 27 as on 05 Apr, 2024
  • Founders Pavan Asalapuram
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Empe Diagnostics Private Limited
  • Date of Incorporation 30 Oct, 2019
  • Jurisdiction Hyderabad, Telangana, India
Operational Areas
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    $693.33 K (USD)
    37.43
    as on Mar 31, 2023
  • Net Profit
    $69.62 K (USD)
    645.87
    as on Mar 31, 2023
  • EBITDA
    $125.41 K (USD)
    141.41
    as on Mar 31, 2023
  • Total Equity Funding
    $1.15 M (USD)

    in 5 rounds

  • Latest Funding Round
    $52.86 K (USD), Grant

    Feb 28, 2023

  • Investors
  • Employee Count
    27

    as on Apr 05, 2024

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

People of EMPE Diagnostics

Headcount 10-50
Employee Profiles 10
Board Members and Advisors 10
Employee Profiles
People
Gayathri Ramasubban
Manger of Clinical Affairs, India
People
Lydia Prasanna
Manager of QA & RA, India
People
Bharath Narikimilli
Accounts & Operations Officer, India
People
Shekar Patteti
Maintenance Executive

Unlock access to complete

Board Members and Advisors
people
Rakesh Kumar Srivastava
Advisor
people
Jenny Göransson
Advisor
people
Rahagvendra Goud
Advisor
people
Sanjeev Kumar Gupta
Advisor & Board Member, India

Unlock access to complete

Funding Insights of EMPE Diagnostics

EMPE Diagnostics has successfully raised a total of $1.15M across 5 strategic funding rounds. The most recent funding activity was a Grant round of $52.86 thousand completed in February 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in EMPE Diagnostics

EMPE Diagnostics has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include European Union, EIC Fund and Almi Invest.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Government agency and accelerator focusing on innovative startups and SMEs
Locked Locked Locked
Multiple sectors are invested in by corporate-backed Almi Invest.
Locked Locked Locked
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
Locked Locked Locked
Premium access

Investor details for EMPE Diagnostics

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by EMPE Diagnostics

Investments
Premium access

Investment portfolio details for EMPE Diagnostics

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - EMPE Diagnostics

Premium access

Detailed financials for EMPE Diagnostics

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Empe Diagnostics Comparisons

EMPE Diagnostics Primary company
Description
Point-of-care tests for TB mutation detection are developed.
Location
Solna, Sweden
Founded Year
2015
Annual Revenue
$693.33 K (USD)
Net Profit
$69.62 K (USD)
EBITDA
$125.41 K (USD)
Employees
27
As of 2024
Premium access

Peer comparison for EMPE Diagnostics

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of EMPE Diagnostics

EMPE Diagnostics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as OpGen, QuantuMDx, Oxford Immunotec, Avails Medical and Resistell, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Developer of diagnostics and bioinformatics platforms for providers
Locked Locked Locked
Handheld diagnostic and sequencing devices are developed for personalized healthcare.
Locked Locked Locked
Immune markers are utilized by Oxford Immunotec for disease diagnostics.
Locked Locked Locked
Point-of-care devices are developed for infection diagnosis and treatment optimization.
Locked Locked Locked
Antibiotic susceptibility testing is provided via bacterial movement detection.
Locked Locked Locked
Develops rapid assay medical tests that use a single drop of blood to test for a variety of common conditions, illnesses and diseases
Premium access

Detailed competitors of EMPE Diagnostics

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Empe Diagnostics

Premium access

Complete news archive for EMPE Diagnostics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about EMPE Diagnostics

EMPE Diagnostics was founded in 2015 and raised its 1st funding round 3 years after it was founded.

EMPE Diagnostics is headquartered in Solna, Sweden.

Pavan Asalapuram is the current CEO of EMPE Diagnostics. They have also founded this company.

EMPE Diagnostics is a funded company, having raised a total of $1.15M across 5 funding rounds to date.

As of Apr 05, 2024, the latest employee count at EMPE Diagnostics is 27.

Annual revenue of EMPE Diagnostics is $693.33K as on Mar 31, 2023.

EMPE Diagnostics was founded in 2015 in Solna, Sweden, within the medical diagnostics sector. Focus is placed on early-stage, point-of-care confirmatory tests for infectious diseases, particularly antimicrobial resistance in tuberculosis. The miniMDR-TB product identifies key mutations like rpoB 531 and katG 315 via visual signals on lateral flow strips in under 60 minutes. The miniXDR-TB test extends detection to multiple genetic markers in microscopy-positive samples during the same timeframe.

EMPE Diagnostics's top competitors include QuantuMDx, Avails Medical and OpGen.

EMPE Diagnostics has 3 investors. Key investors include European Union, EIC Fund, and Almi Invest.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available